Saxagliptin + Metformin (Xr) Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets XR
Available Strengths: 2.5 mg/1000 mg, 5 mg/500 mg, 5 mg/1000 mg
Reference Brands: Kombiglyze XR®(EU & US)
Category:
Diabetes
Saxagliptin + Metformin (XR) combines a DPP-4 inhibitor and a biguanide. Saxagliptin enhances incretin activity, boosting insulin and reducing glucagon. Metformin decreases hepatic glucose production. Together, they improve glycemic control with low hypoglycemia risk, weight neutrality, and convenient once-daily dosing—ideal for managing type 2 diabetes effectively.
Saxagliptin + Metformin (XR) tablets is available in Tablets XR
and strengths such as 2.5 mg/1000 mg, 5 mg/500 mg, 5 mg/1000 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Saxagliptin + Metformin (XR) tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Saxagliptin + Metformin (XR) tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Saxagliptin + Metformin extended-release tablets are approved for type 2 diabetes treatment in both the USA and EU. In the US, they are marketed as Kombiglyze XR®, approved via an NDA and regulated under 21 CFR, with mandatory labeling for lactic acidosis risk and heart failure. Compliance with GMP and post-marketing pharmacovigilance is essential. In the EU, the product is known as Komboglyze® and is authorized via the centralized procedure. It requires a CTD format, Risk Management Plan (RMP), PSURs, and full pharmacovigilance compliance. For regulatory support and sourcing, visit PharmaTradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing